Upadacitinib for Induction of Remission in Paediatric Crohn's Disease: An International Multicentre Retrospective Study
Alimentary Pharmacology & Therapeutics · 2025
DOI: 10.1111/apt.70016 ↗At a glance
Multizentrische Studie in Alimentary Pharmacology & Therapeutics, 2025. Written by Shlomi Cohen and 34 co-authors. Institution: Pediatric Gastroenterology Institute, "Dana-Dwek" Children's Hospital, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel and the Faculty of Medical …. Major MEDLINE topics: Crohn Disease, Heterocyclic Compounds, 3-Ring. Cited 29 times so far (Crossref); 34 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: NIDDK NIH HHS.
Abstract (original language)
Background
There are scarce data available on upadacitinib in children with Crohn's disease (CD).
Aim
To evaluate the effectiveness and safety of upadacitinib as an induction therapy in paediatric CD.
Methods
This was a multicentre retrospective study between 2022 and 2024 of children treated with upadacitinib for induction of remission of active CD conducted in 30 centres worldwide affiliated with the IBD Interest and Porto group of the ESPGHAN. We recorded demographic, clinical and laboratory data and adverse events (AEs) at week 8 post‐induction. The analysis of the primary outcome was based upon the intention‐to‐treat (ITT) principle.
Results
We included 100 children (median age 15.8 [interquartile range 14.3–17.2]). All were previously treated with biologic therapies including 89 with ≥ 2 biologics. At the end of the 8‐week induction period, we observed clinical response, clinical remission and corticosteroid‐ and exclusive enteral nutrition‐free clinical remission (CFR) in 75%, 56% and 52%, respectively. By the end of induction, 68% had achieved normalisation of C‐reactive protein, and 58% had faecal calprotectin (FC) < 150 mcg/g. There was combined CFR and FC remission in 13/31 children with available data at 8 weeks (13% of the ITT population). AEs were recorded in 24 children; the most frequent was acne in 12. Two AEs (severe acne and hypertriglyceridemia) led to discontinuation of therapy.
Conclusion
Upadacitinib is an effective induction therapy for refractory paediatric CD. Efficacy should be weighed against the potential risks of AEs.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Pediatric Gastroenterology Institute, "Dana-Dwek" Children's Hospital, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel and the Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel.
- Division of Pediatric Gastroenterology, Susan and Leonard Feinstein IBD Clinical Center, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
- University of Washington Medical School, Seattle, Washington, USA.
- Department of Paediatrics, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic.
- Division of Gastroenterology, Hepatology and Nutrition, Children's Hospital of Philadelphia, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
- Translational Gastroenterology Unit, University of Oxford, Oxford, UK.
ORCID profiles: Elizabeth A Spencer, Michael T Dolinger, David L Suskind, Katarina Mitrova, Holm H Uhlig, Paul Henderson, Dror S Shouval, Ben Kang, Kaija-Leena Kolho, Lorenzo Norsa, Firas Rinawi, Naire Sansotta, Maya Granot, Dan Turner
Funding
- NIDDK NIH HHS
Cite
APA
Cohen, S., Spencer, E. A., Dolinger, M. T., Suskind, D. L., Mitrova, K., Hradsky, O., Conrad, M. A., Kelsen, J. R., Uhlig, H. H., Tzivinikos, C., Henderson, P., Wlazlo, M., Hackl, L., Shouval, D. S., Bramuzzo, M., Urlep, D., Olbjørn, C., D'Arcangelo, G., Pujol-Muncunill, G., …, & Yerushalmy-Feler, A. (2025). Upadacitinib for Induction of Remission in Paediatric Crohn's Disease: An International Multicentre Retrospective Study. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.70016
Vancouver
Cohen S, Spencer EA, Dolinger MT, Suskind DL, Mitrova K, Hradsky O, et al. Upadacitinib for Induction of Remission in Paediatric Crohn's Disease: An International Multicentre Retrospective Study. Alimentary Pharmacology & Therapeutics. 2025. doi:10.1111/apt.70016
BibTeX
@article{Cohen2025,
author = {Cohen, Shlomi and Spencer, Elizabeth A and Dolinger, Michael T and Suskind, David L and Mitrova, Katarina and Hradsky, Ondrej and Conrad, Máire A and Kelsen, Judith R and Uhlig, Holm H and Tzivinikos, Christos and Henderson, Paul and Wlazlo, Magdalena and Hackl, Lukas and Shouval, Dror S and Bramuzzo, Matteo and Urlep, Darja and Olbjørn, Christine and D'Arcangelo, Giulia and Pujol-Muncunill, Gemma and Yogev, Dotan and Kang, Ben and Gasparetto, Marco and Rungoe, Christine and Kolho, Kaija-Leena and Hojsak, Iva and Norsa, Lorenzo and Rinawi, Firas and Sansotta, Naire and Rimon, Ramit Magen and Granot, Maya and Scarallo, Luca and Trindade, Eunice and Rodríguez-Belvís, Marta Velasco and Turner, Dan and Yerushalmy-Feler, Anat},
title = {Upadacitinib for Induction of Remission in Paediatric Crohn's Disease: An International Multicentre Retrospective Study},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2025},
doi = {10.1111/apt.70016}
}
EUVIMED